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SUMMARY
The enormous dynamic range of human bodily fluid proteomes poses a significant challenge for current MS-based proteomic technologies as it makes it especially difficult to detect low abundant proteins in human biofluids such as blood plasma, an essential aspect for successful biomarker discovery efforts. Here, we present a novel tandem IgY12-SuperMix immunoaffinity separation system for enhanced detection of low abundant proteins in human plasma. The tandem IgY12-SuperMix system separates ~60 abundant proteins from the low abundant proteins in plasma, which allows for significant enrichment of low abundant plasma proteins in the SuperMix flow-through fraction. High reproducibility of the tandem separations was observed in terms of both sample processing recovery and LC-MS/MS identification results based on spectral count data. The ability to quantitatively measure differential protein abundances following application of the tandem separations was demonstrated by spiking six non-human standard proteins at three different levels into plasma. A side-by-side comparison between the SuperMix flow-through and IgY12 flow-through samples analyzed by both 1D and 2D LC-MS/MS revealed a 60-80% increase in proteome coverage as a result of the SuperMix separations, which suggests significantly enhanced detection of low abundant proteins. A total of 695 plasma proteins were confidently identified in a single analysis (with a minimum of two peptides per protein) by coupling the tandem separation strategy with 2D-LC-MS/MS, including 42 proteins with reported normal concentrations of ~100 pg/mL to 100 ng/mL. The concentrations of two selected proteins, M-CSF and MMP8, were independently validated by ELISA as 202 pg/mL and 12.4 ng/mL, respectively. Evaluation of binding efficiency revealed 45 medium-abundant proteins were efficiently captured by the SuperMix column with >90% retention. Taken together, these results illustrate the potential broad utilities of this tandem IgY12-SuperMix strategy for proteomic applications involving human biofluids, where effectively addressing the dynamic range challenge of the specimen is imperative.
INTRODUCTION
There has been tremendous interest in using advanced proteomics technologies to analyze human bodily fluids, such as plasma and serum for the purpose of discovering and verifying new candidate protein biomarkers applicable to different diseases . 1, 2 These technologies are challenged to detect low-abundance physiologically-relevant proteins with extremely wide dynamic ranges in concentrations (i.e., more than 10 orders of magnitude for protein concentrations reported in human plasma) 3, 4 . Despite significant recent advances, current proteomics technologies still fall short of being able to reliablely detect low ng/mL to sub-ng/mL protein concentrations in blood plasma, a level of detection often required for discovering disease-specific biomarkers 4 . Many different fractionation/separation techniques have been developed and applied in a multidimensional fashion to enhance detection of low abundant proteins in human biofluids 5, 6 . One of the most commonly applied strategies to potentially alleviate the "masking" effect created by the presence of the highly abundant proteins is to remove them 7 . In the human plasma proteome, 22 proteins are responsible for 99% of the bulk mass of the total protein content in human plasma; this leaves perhaps hundreds of thousands of other proteins in only 1% of the protein mass 3 . As a result, effective strategies for removing these 22 proteins (and possibly other medium-abundant proteins) should greatly enhance detection of low abundant proteins within this important biofluid proteome.
Multi-component immunoaffinity separation strategies are increasingly being applied in various biomarker discovery applications to remove the abundant proteins and achieve comprehensive surveys of the biofluid proteomes. In such approaches, affinity-purified polyclonal antibodies (pAbs), typically immobilized by cross-linking on either chromatographic matrices or microbeads are used as immunoaffinity reagents to specifically remove abundant In this study, we present a new Seppro ® IgY-SuperMix immunoaffinity separation system for its ability to enhance detection of low abundant proteins in human plasma. The new SuperMix system has been designed to be applied in tandem with the IgY12 system for capturing ~50 moderately abundant proteins in addition to the 12 most abundant proteins in plasma.
Herein, we present results from this study that illustrate the potential for enhanced detection of low abundant proteins, as well as the reproducibility of the SuperMix partitioning method for LC-MS/MS plasma proteome profiling. Generation of IgY-SuperMix LC2 Column. To generate an immunoaffinity column with a mixture of antibodies that will bind to those moderately abundant proteins in human plasma, a plasma sample was initially depleted of the 12 highest abundant proteins (HAP) using an IgY12 column. The flow-through fraction containing medium or low abundant proteins was used as a mixture of antigens for immunizing chickens and generating a mixture of polyclonal IgY antibodies. The IgY12 depleted flow-through fraction was also used as affinity ligands and conjugated to CNBr-activated Sepharose TM 4B (GE Healthcare, Piscataway, NJ) for preparing an antigen affinity column (Antigen-Affinity Column), which was used to purify the antibodies from the total IgYs isolated from the chickens immunized with the IgY12-depleted fraction. Manufacturer's recommendations were followed in these separations, which were similar to those previously described 7 . The same three buffers were utilized (dilution/washing: 10 mM
Tris-HCl, 150 mM NaCl, pH 7.4 (TBS); stripping/elution buffer: 100mM glycine, pH 2.5; neutralization buffer: 100 mM Tris-HCl, pH 8.0) in a separation scheme that consisted of sample loading-washing-eluting-neutralization, followed by a re-equilibration scheme for a total cycle time of ~70 min. The flow-through and bound (or eluted) fractions were collected separately.
Following the IgY12 separations, the flow-through fractions were concentrated in Amicon® Ultra-15 (5 kDa nominal molecular weight limit, Millipore, Billerica, MA)
concentrators followed by buffer exchange to 50 mM NH 4 HCO 3 (pH 8.0). Protein concentration was then determined by BCA protein assay (Pierce).
The concentrated IgY12 flow-through fractions were then partitioned using a Seppro ® SuperMix LC2 (6.4 × 63.0 mm) immunoaffinity column on the same HPLC system. The separation conditions using the SuperMix column were similar to that described for the IgY12 LC2 separation 7 . Both the flow-through and bound fractions from the SuperMix LC2 column were collected and concentrated as described above with buffer exchange to 50 mM NH 4 HCO 3 , and protein concentration measured using BCA protein assay (Pierce).
To demonstrate the measurements of differential protein abundances, six non-human standard proteins were spiked into three 1 mL human plasma samples at 1 μg/mL, 5 μg/mL, and 25 μg/mL concentrations, respectively. The six proteins spiked into plasma were bovine carbonic anhydrase 2, chicken ovalbumin, horse myoglobin, bovine alpha-lactalbumin, bovine cytochrome C, and bovine beta-lactoglobulin. Each plasma sample with spiked protein was subjected to triplicate tandem IgY12-SuperMix immunoaffinity separations with 250 μL starting plasma for each replicate. Both the SuperMix flow-through and bound fractions for each of the replicate experiments were concentrated as described above. Because false positive peptide/protein identifications are a common concern in proteomics investigations, we developed and applied a set of criteria based on the reversed database approach for filtering the raw data to limit false positive identifications to <5% at the unique peptide level as previously described 13, 14 . The reversed human protein database was created by reversing the order of the amino acid sequences for each protein, and the false positive rate (FPR) for peptide identifications was estimated by dividing the number of unique peptides identified from the reversed database search (N R ) by the number of unique peptides identified from the normal database search (N N ), i.e., FPR = N R / N N . Table 1 summarizes the cross correlation score (Xcorr) and delta correlation (ΔCn) values along with tryptic cleavage states for filtering the SEQUEST raw data. A false positive rate of ~4% was observed at the unique peptide level following such filtering for this study.
Protein
ProteinProphet™ software was employed as a clustering tool to generate a list of nonredundant proteins or protein groups 15 . Peptides that passed the filtering criteria were assigned the identical probability score of 1 and entered into the software program (done exclusively for cluster analysis) to generate a final list of non-redundant proteins/protein groups. One protein IPI number was randomly selected to represent each corresponding protein group that consists of a number of database entries. Only those proteins or protein groups with two or more unique peptide identifications were considered as confident protein identifications.
Enzyme-Linked Immunosorbent Assay (ELISA). The plasma protein concentrations
for M-CSF and MMP8 were determined in triplicate using Quantikine ELISA kits (R&D Systems, Minneapolis, MN) following manufacturer's instructions. Each sample was analyzed at three different dilutions to determine the optimal dilution.
RESULTS
Tandem IgY12-SuperMix Immuno-separation Strategy. The scheme used to generate the SuperMix column is shown in Figure 1 . The concept behind the SuperMix immunoaffinity separation is that antibodies can be generated against mixed antigens, such as the proteins present in human plasma. Because the antibody titers correspond to the abundance and the immunogenicity of the proteins 16 ,the assumption is that moderate-abundant proteins in human plasma may lead to much higher immune response than lower-abundant proteins. As a result, a purified,mixture of these antibodies can be used to capture a large number of medium-abundant proteins, especially when applied in tandem with high-abundant protein removal strategy such as Comparable reproducibility was observed for both SuperMix and IgY12 flow-through fractions, which suggests the reproducibility of the tandem IgY12-SuperMix separations is similar to that of the single IgY12 separations.
Quantitation of Differential Protein Abundances.
A standard addition experiment using six non-human standard proteins spiked into the original plasma at three different levels,
i.e., 1 μg/mL, 5 μg/mL, 25 μg/mL was performed to evaluate the ability for relative quantitation of protein abundances applying the tandem separation strategy. Following triplicate immunoaffinity separations, both the SuperMix flow-through and bound fractions from the three plasma samples were analyzed using LC-MS/MS to generate spectral count data for relative quantitation. The spiked proteins were not detected in the SuperMix bound fraction except for beta-lactoglobulin, which was observed at the 25 μg/mL spiked level in the bound fraction with an average spectral count of 7 across replicates.
The spectral count data for the six spiked standard proteins as measured in the flowthrough samples are plotted in Figure 3 . As shown, reproducible spectral count data within the triplicate experiments were observed for all six proteins at each of the three concentration levels with the sole exception of cyctochrome c, which was not detected at the lowest level (1 μg/mL). IgY12 flow-through were in the low μg/mL to high ng/mL range, such as HGFA (500 ng/mL) and CD14 (1.4 μg/mL), which is in agreement with our recent report 4 . The lists of proteins and peptides identified using SuperMix and IgY12 are available as Supplemental Tables I and II, respectively, along with corresponding spectral count information.
The enhanced detection of low abundant proteins achieved using SuperMix is further illustrated in Figure 5 , which displays protein concentrations in the range of ~200 pg/mL to 100 ng/mL (based on previous literature data) for 40 low abundant proteins detected in the flow- Table I .
DISCUSSION
One of the greatest challenges for applying advanced MS-based proteomics to clinical biomarker discovery efforts remains the ability to effectively detect low abundant proteins in complex mixtures. Many different fractionation/separation techniques have been developed and applied in a multidimensional fashion at both the protein and peptide levels to address this dynamic range challenge 5, 20, 21 . Essentially all of the chromatography-based separation and fractionation approaches provide some degree of enrichment (or focusing) of a specific subset of low abundant proteins to achieve improved detection. Immunoaffinity chromatography with multiplexed antibodies that target relatively abundant proteins is a commonly used technique for human biofluid proteome profiling 9, 10 . In LC format, immunoaffinity separations offer an effective strategy for separating high-abundant from relatively low abundant proteins in a highly reproducible fashion 7, 12 , thus alleviating the "masking" effect of high-abundant proteins.
However, in spite of advances in recent years, immunoaffinity separation strategies have been limited to the number of antibodies that can be multiplexed on the LC column (currently limited to 20 proteins).
In this work, we introduced a novel tandem IgY12-SuperMix immunoaffinity separation strategy that allows effective binding of ~57 high-or medium-abundant proteins onto the IgY12-SuperMix column. This method of separating >50 abundant proteins from low abundant proteins has led to significant improvements, as evidenced by LC-MS/MS. Improvements in plasma proteome coverage (~60-80%) ( Figure 4 ) and detection sensitivity has now allowed identification of a number of low concentration (ng/mL) proteins, including known cytokines and growth factors from a normal human subject ( Figure 5 and Table 4 ). Importantly, one of the cytokines (M-CSF) has been confirmed to be present at ~200 pg/mL based on ELISA assay
results. These results demonstrate that tandem IgY12-SuperMix immunoaffinity separations with high reproducibility offer an effective means to dig deeper into complex biofluid proteomes for quantitative clinical applications. Unlike other fractionation approaches that typically produce many fractions, the immunoaffinity separations only generate two fractions (the flow-through and bound fractions); thus improvement are achieved without a significant reduction in analytical throughput. Moreover, the separations can be fully automated on a HPLC system; with only a slight increase in sample processing due to the addition of concentration and buffer exchange steps. Finally, immunoaffinity columns typically allow more than 100 separations per column, which alleviates the concern of batch-to-batch variations of affinity columns since a given biological study can be typically completed using a single column.
One of the general concerns in applying immunoaffinity columns is the extent of nonspecific binding. We recently demonstrated that the extent of non-specific or specific binding to a column is reproducible for a given protein 7 . Although we did not observe strong evidence of non-specific binding on the SuperMix column in this study, we believe the most likely use of the SuperMix column would be as a separation/fractionation tool such that both the bound and flowthrough fractions are analyzed to achieve more complete proteome profiling, instead of using it A potential issue of the SuperMix column is that it contains an undefined mixture of antibodies that are present at various amounts. Based on our data, many proteins could be partially bound to the column; therefore, the SuperMix column should be utilized as a fractionation technique with both the bound and flow-through fractions analyzed for better evaluation of potential abundance differences between conditions. The partial protein binding to the column could amplify the abundance differences depending on the extent of binding without affecting the "directions" of these abundance changes. For example, for a protein present with 1 μg quantity in one ample and 3 μg in another sample (i.e., a 3-fold difference), and a column has antibody capacity to bind 0.5 μg of the protein for both samples, the relative concentration differences between the two samples will be amplified to 5-fold (0.5 vs. 2.5) following the SuperMix separations. Given the reproducibility of the SuperMix separations, such changes in amplitudes should not have a detrimental effect on our ability to identify statistically significant abundance differences for candidate biomarkers. Nevertheless, one does need to keep in mind that observed amplitudes of protein concentration differences may not exactly reflect the true quantitative differences in original samples if there is partial protein binding. .
Since generation of the SuperMix column is based on mixed antigens from IgY12-depleted human plasma, the amount of antibodies available for each protein will depend on the immuno-reactivity of the proteins in the host system. In fact, we observed several relatively high-abundant proteins that were not effectively bound by the SuperMix column. Individual antibodies of these proteins may be developed and added to further enhance the performance of the SuperMix column. If available antibodies are limited, then optimization of the sample loading step may allow more proteins to be effectively captured.
To conclude, the improved proteome coverage/enhanced detection of low abundant proteins, reproducibility, and the ability for relative quantitation demonstrate the utility of tandem IgY12-SuperMix immunoaffinity separations for clinical biomarker discovery applications involved with human biofluids. These tandem separations can be coupled with either LC-MS-based or gel-based approaches with or without further fractionation. We anticipate that this tandem IgY12-SuperMix strategy may also significantly enhance the effectiveness of directed MS in the multiple-reaction monitoring mode for candidate biomarker verification [22] [23] [24] . a The spectral count data from triplicate analyses of the flow-through and bound fraction of SuperMix separations are presented for the listed moderately abundant proteins. b The capture efficiency is used to estimate the percentage for a given protein being captured by the SuperMix column, which was estimated for each protein by dividing the spectral count for each protein from the bound fraction by the sum of spectral counts from the bound fraction and flow-through fraction, i.e. B/(B+FT). The estimated capture efficiency will be less accurate for proteins with only a few spectral counts. Even if 0 count was observed in flow-through, it does not mean a complete capture by the column; therefore, these proteins were represented as >99%. 
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